Viking Therapeutics Inc (VKTX)

[XenaLives]

At some point medical practice needs to stop treating symptoms and start treating the cause of the disease. Long term conditions and diseases of aging are usually due to systemic dysfunction on the mitochondrial level. Treating symptoms just leads to additional dysfunction known as "side effects".

These commercials drive me crazy. Physicians frequently over prescribe and improperly prescribe psychiatric meds, see this link:tarditive dyskenesia causes

https://www.youtube.com/watch?v=5JAE28ts_3M

https://www.youtube.com/watch?v=gLB5XWAQzBE

The answer is to tread dysregulation at the molecular level without side effects:

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders.
Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients’ lives. The company’s clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of X-linked adrenoleukodystrophy (X-ALD).

Viking’s other programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator. In a Phase 2 trial in patients recovering from hip fracture, patients who received VK5211 experienced significant improvements in measures of lean body mass compared with patients who received placebo. Other programs also include two earlier-stage programs targeting metabolic diseases and anemia. The company holds exclusive worldwide rights to a portfolio of five therapeutic programs, including those noted above, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated.

https://www.vikingtherapeutics.com/about/